Over 65 million people are affected with
epilepsy worldwide. A variety of genetic and environmental factors have been
associated with epilepsy and seizures. In the case of epilepsy, DNA methylation
has been deemed one of the principal epigenetic mechanisms leading to epilepsy.
These affect genomic reprograming, tissue-specific gene expression and global
gene silencing without affecting the sequence.
It has been seen that many of these DNA
methylations are present at the promoters of genes, resulting in a decrease of
gene expression. Besides promotors, an inverse relationship between gene
expression and DNA methylation has been seen in exons and introns. Not only has
it been discovered that selective changes in genome-wide DNA methylation and
increased DNA methyltransferase are associated with temporal lobe epilepsy
(TLE), but also that ketogenic diets could attenuate seizure progression though
DNA methylation.
The work of Xi Liu et al. was focused on
analyzing the pattern of genome wide DNA methylation and gene expression using
methylated DNA immunoprecipitation linked with sequencing. As a result, they
were able to distinguish a new pattern of DNA methylation associated with
refractory epilepsy patients. They also found that there was no significant
difference between epileptic samples and controls in genome, CpG, CHG, and CHH
coverage distribution and that differentially methylated regions were
discovered on all genes except for the male Y chromosome. Generally, no
significant relationship in modulation was found between DNA methylation and
gene expression. Xi Liu et al, also working towards generating DNA methylation
and gene expression profiles to prove the relationship between DNA methylation
and gene expression via distribution of hyper-, hypo- and unmethylated gene
expression levels in different elements.
The importance of this paper is that is the first genome wide report on
DNA methylation and gene expression in refractory epilepsy patients. Over 62
differentially expressed genes were found to be correlated with epilepsy and
seizures. However, the similarity in results between epileptic samples and the
controls indicated no significant difference in global DNA methylation and gene
expression. That is, the change in DNA methylation in the study is no
corresponded with alterations in gene expression.
Reference: Liu, X., Ou, S., Xu, T., Liu, S. Yuan, J., Huang, Y., Qin, L., Yang, H., Chen, L., Tan, X., Chen, Y., (November 26,2016), New Differentially Expressed Genes and Differential DNA Methylation Underlying Refractory Epilepsy. Oncotarget. Retrieved from http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=13642
Tetrapeptide-26 is an innovative anti-aging tetrapeptide, designed using advanced molecular biology and inspired by epigenetic science, to boost the expression of clock genes. Tetrapeptide-26
ReplyDelete